404 related articles for article (PubMed ID: 27402803)
1. Direct oral anticoagulants: unique properties and practical approaches to management.
Barnes GD; Kurtz B
Heart; 2016 Oct; 102(20):1620-6. PubMed ID: 27402803
[TBL] [Abstract][Full Text] [Related]
2. Which oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
[No Abstract] [Full Text] [Related]
3. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
[No Abstract] [Full Text] [Related]
4. Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.
Arbit B; Hsu JC
Clin Cardiol; 2015 Nov; 38(11):684-91. PubMed ID: 26173428
[TBL] [Abstract][Full Text] [Related]
5. Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis.
Chan YH; Lee HF; Chao TF; Wu CT; Chang SH; Yeh YH; See LC; Kuo CT; Chu PH; Wang CL; Lip GYH
Cardiovasc Drugs Ther; 2019 Dec; 33(6):701-710. PubMed ID: 31745687
[TBL] [Abstract][Full Text] [Related]
6. Updated guidelines on outpatient anticoagulation.
Wigle P; Hein B; Bloomfield HE; Tubb M; Doherty M
Am Fam Physician; 2013 Apr; 87(8):556-66. PubMed ID: 23668445
[TBL] [Abstract][Full Text] [Related]
7. The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.
Alamneh EA; Chalmers L; Bereznicki LR
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28177198
[TBL] [Abstract][Full Text] [Related]
8. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
9. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.
Martin K; Beyer-Westendorf J; Davidson BL; Huisman MV; Sandset PM; Moll S
J Thromb Haemost; 2016 Jun; 14(6):1308-13. PubMed ID: 27299806
[No Abstract] [Full Text] [Related]
10. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
Milling TJ; Ziebell CM
Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
[TBL] [Abstract][Full Text] [Related]
11. [Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Panchenko EP
Kardiologiia; 2011; 51(11):83-90. PubMed ID: 22117775
[No Abstract] [Full Text] [Related]
12. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
13. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
Becattini C; Vedovati MC; Agnelli G
Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
[TBL] [Abstract][Full Text] [Related]
14. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
Williams BA; Evans MA; Honushefsky AM; Berger PB
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban in venous thromboembolism and stroke prevention: an appraisal.
Proietti M; Lip GY
Vasc Health Risk Manag; 2016; 12():45-51. PubMed ID: 27013883
[TBL] [Abstract][Full Text] [Related]
16. Dabigatran use in elderly patients with atrial fibrillation.
Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
[TBL] [Abstract][Full Text] [Related]
17. Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
Wang KL; Chiu CC; Giugliano RP; Tan DS; Lin CY; Lai EY; Goto S; Chiang CE
J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):857-864. PubMed ID: 29239808
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula.
Sjögren V; Grzymala-Lubanski B; Renlund H; Friberg L; Lip GY; Svensson PJ; Själander A
Thromb Haemost; 2015 Jun; 113(6):1370-7. PubMed ID: 25716771
[TBL] [Abstract][Full Text] [Related]
19. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
[TBL] [Abstract][Full Text] [Related]
20. The new era of anticoagulation.
Skeik N; Rumery KK; Rodriguez GT
Ann Vasc Surg; 2014 Feb; 28(2):503-14. PubMed ID: 24412298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
